Coronavirus Update: J&J’s Single Dose Stands Out From COVID Vaccine Crowd
Phase III Planned For September
J&J is a few months behind companies like Moderna, Pfizer and AstraZeneca in the race to develop a vaccine, but a safe and effective single dose immunization would be a game changer.
You may also be interested in...
Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials.
The agreement will give all EU member states the option to access the drug major's investigational COVID-19 vaccine dubbed AZD1222 "in an equitable manner at no profit during the pandemic."
Johnson & Johnson has added a manufacturing base in India’s Biological E as part of a global supply chain for its COVID-19 vaccine candidate. While Biological E will make 400-500 million dosages for the US firm, it has licensed for development another SARS-CoV-2 vaccine candidate from US-based Baylor College of Medicine.